Thoracic Pathology Course 2023 - On Demand

Sunday, October 15, 2023, 7:00 AM - Wednesday, July 31, 2024, 11:00 PM

This on demand course provides a current review of thoracic pathology with clinical, radiologic, and molecular correlations. The program consists of a series of presentations, including some multidisciplinary sessions on lung cancer, interstitial lung disease, and non-neoplastic lung disease. Updates on the 2021 WHO Classification of Lung Tumors, the 8th Edition TNM Staging Classification, the ATS/ERS Classification of Idiopathic Interstitial Pneumonias, and Guidelines for Diagnosis of Hypersensitivity Pneumonitis are included. Most speakers will be expert lung pathologists, but there will also be clinical and radiologic presentations by well-known thoracic clinicians and radiologists. Their presentations will illustrate the importance of a multidisciplinary approach to solving difficult problems in thoracic disease.

This program is co-sponsored with Massachusetts General Hospital and endorsed by the Pulmonary Pathology Society.

Target Audience

The target audience for this on demand program includes pathologists, pulmonologists, thoracic surgeons, and radiologists, including physicians in training.

On Demand Content and Access Instructions

This on demand contains 3O+ recorded lectures from the live program that took place live on September 29-October 1, 2023, along with PDFs of the faculty presentations (slides). For a complete list of available sessions and speakers, view the live course brochure.

To purchase this on demand program, select the Register tab above and complete all necessary information including payment. Once you have successfully registered, access to the course materials will be available under the Course Content tab.

This on demand program is available for purchase through April 30, 2024. Once purchased, access to the content along with with claiming credit will be available through July 31, 2024.

1. State current concepts in lung, pleural and mediastinal pathology
2. Recall the clinically relevant advances and technology in molecular pathology of lung cancer
3. Define the importance of correlation between clinical, radiologic and pathologic data in diagnosis and management of interstitial lung disease
4. Recognize the significance of lung biopsy and multidisciplinary correlation for the diagnosis of non-neoplastic lung disease with a focus on interstitial pneumonias, hypersensitivity pneumonitis and acute lung injury
5. Comprehend the most recent histologic concepts in lung cancer diagnosis and classification including problematic issues related to spiral CT screening
6. Recognize the differential diagnosis for mediastinal and pleural lesions
7. Describe the usefulness of cytology in pulmonary, pleural and mediastinal diagnoses

On Demand Fees

• Physicians (MDs, DOs, and PhDs): $895
• Pathology Assistants, Fellows, Residents, RNs, and Other Healthcare Providers: $450
• MSK Employees: Complimentary

Discounts and Complimentary Registration

• Complimentary registration is available for registrants registrants residing in low and lower-middle income countries as defined by The World Bank. If you qualify for complimentary registration, please submit a request here for a complimentary promotion code to use at registration.
• Complimentary registration is available for Massachusetts General Hospital residents and fellows. If you are a MGH resident or fellow, please submit a request here for a complimentary promotion code to use at registration.
• A discounted rate is available for MSK Alumni and MSK Cancer Alliance members to purchase this on demand. If you are a member of one of these groups, please submit your request here for this discount.

Please note that after your payment has been processed, no further promotional discount adjustments will be made to your registration.

This Memorial Sloan Kettering Continuing Medical Education on demand program is non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 19.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPath CC Recognition Statement

This activity will offer 19.75 Lifelong Learning (CME) credit towards the American Board of Pathology’s Continuing Certification program.

Please be advised that ABPath points will be awarded approximately 45 days after the submission of your evaluation.

 

Recorded/Review Date: September 29-October 1, 2023; Original Release Date: October 15, 2023; Termination Date: July 31, 2024

Course Directors 

William D. Travis, MD 
Memorial Sloan Kettering Cancer Center

Mari Mino-Kenudson, MD
Massachusetts General Hospital

 

Course Co-directors 

Natasha Rekhtman, MD, PhD 
Memorial Sloan Kettering Cancer Center 

Lida Hariri, MD, PhD
Massachusetts General Hospital

 

Invited Course Faculty 

Mary Beth Beasley, MD 
Mount Sinai 

Alain Borczuk, MD
Northwell Health

Sanja Dacic, MD
Yale School of Medicine

Robert J. Kaner, MD
Weill Cornell

Alan Legasto, MD
Weill Cornell

Andre Moreira, MD
NYU Langone 

Navneet Narula, MD
NYU Langone 

Anjali Saqi, MD
Columbia University

Chen Zhang, MD, PhD
Weill Cornell

 

MSK Course Faculty 

Marina K. Baine, MD, PhD

Darren J. Buonocore, MD

Jason C. Chang, MD

Mohit Chawla, MD

Michelle S. Ginsberg, MD

James M. Isbell, MD, MSCI

Charles M. Rudin, MD, PhD

Jennifer L. Sauter, MD

Soo Ryum Yang, MD

 

Relevant Financial Relationships

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.